Works matching IS 00099236 AND DT 2022 AND VI 112 AND IP 4
Results: 23
From Genes to Endogenous Substrates: Towards a Better Understanding of Drug Metabolizing Enzymes.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 4, p. 741, doi. 10.1002/cpt.2724
- Publication type:
- Article
Highlights.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 4, p. 744, doi. 10.1002/cpt.2720
- Publication type:
- Article
ASCPT News.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 4, p. 746, doi. 10.1002/cpt.2719
- Publication type:
- Article
In This Issue.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 4, p. 739, doi. 10.1002/cpt.2718
- Publication type:
- Article
Development of a Translational Exposure‐Bracketing Approach to Streamline the Development of Hormonal Contraceptive Drug Products.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 4, p. 909, doi. 10.1002/cpt.2690
- By:
- Publication type:
- Article
Ziritaxestat Drug–Drug Interaction with Oral Contraceptives: Role of SULT1E1 Inhibition.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 4, p. 901, doi. 10.1002/cpt.2689
- By:
- Publication type:
- Article
Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID‐19, in Subjects With Renal Impairment.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 4, p. 892, doi. 10.1002/cpt.2688
- By:
- Publication type:
- Article
Physiologically‐Based Pharmacokinetic Modeling‐Guided Dose Management of Oral Anticoagulants when Initiating Nirmatrelvir/Ritonavir (Paxlovid) for COVID‐19 Treatment.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 4, p. 803, doi. 10.1002/cpt.2687
- By:
- Publication type:
- Article
Calibration and Validation of a Mechanistic COVID‐19 Model for Translational Quantitative Systems Pharmacology – A Proof‐of‐Concept Model Development for Remdesivir.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 4, p. 882, doi. 10.1002/cpt.2686
- By:
- Publication type:
- Article
Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 4, p. 873, doi. 10.1002/cpt.2685
- By:
- Publication type:
- Article
Comparative Effectiveness and Safety of Different Combinations of Antithrombotic Regimens in Atrial Fibrillation Patients With Stent Insertions.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 4, p. 864, doi. 10.1002/cpt.2684
- By:
- Publication type:
- Article
Extrapolation of Efficacy from Adults to Pediatric Patients of Drugs for Treatment of Partial Onset Seizures: A Regulatory Perspective.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 4, p. 853, doi. 10.1002/cpt.2681
- By:
- Publication type:
- Article
Post‐Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004–2014.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 4, p. 846, doi. 10.1002/cpt.2679
- By:
- Publication type:
- Article
Combined Conventional Synthetic Disease Modifying Therapy vs. Infliximab for Rheumatoid Arthritis: Emulating a Randomized Trial in Observational Data.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 4, p. 836, doi. 10.1002/cpt.2673
- By:
- Publication type:
- Article
Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 4, p. 791, doi. 10.1002/cpt.2667
- By:
- Publication type:
- Article
Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 4, p. 824, doi. 10.1002/cpt.2665
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 4, p. 731, doi. 10.1002/cpt.2301
- Publication type:
- Article
Characteristics of the Compassionate Use Program in Japan: An Analysis of Expanded Access Clinical Trials from 2016 to 2021.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 4, p. 817, doi. 10.1002/cpt.2641
- By:
- Publication type:
- Article
Analysis of US Food and Drug Administration Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 4, p. 782, doi. 10.1002/cpt.2505
- By:
- Publication type:
- Article
Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 4, p. 770, doi. 10.1002/cpt.2503
- By:
- Publication type:
- Article
Liver Injury Due to Drugs and Viruses: Mechanistic Similarities and Implications for AAV Gene Therapy.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 4, p. 751, doi. 10.1002/cpt.2500
- Publication type:
- Article
Risk‐Based Pharmacokinetic and Drug–Drug Interaction Characterization of Antibody–Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development Perspective.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 4, p. 754, doi. 10.1002/cpt.2448
- By:
- Publication type:
- Article
Molybdenum Cofactor Catabolism Unravels the Physiological Role of the Drug Metabolizing Enzyme Thiopurine S‐Methyltransferase.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 4, p. 808, doi. 10.1002/cpt.2637
- By:
- Publication type:
- Article